 |
Inhibitex Reports Initiation Of Multiple Ascending Dose Trial Of FV-100 For Shingles (Medical News Today) |
Inhibitex, Inc. (NASDAQ: INHX), a biopharmaceutical company focused on the development of products to treat serious infectious diseases, announced today that it has completed a Phase I single ascending dose (SAD) clinical trial and initiated a multiple ascending dose (MAD) trial of FV-100, a highly potent and fast-acting compound being developed to treat shingles (herpes zoster).
More: continued here
This entry was posted on Saturday, August 9th, 2008 and is filed under Chicken Pox. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Leave a comment